Overview

Senescence in Chronic Kidney Disease

Status:
Enrolling by invitation

Trial end date:
2022-06-02

Target enrollment:

Participant gender:

Summary

The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Dasatinib
Quercetin